We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of the Autonomic Nervous System in HIV-Lipodystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00149097
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : May 12, 2008
Information provided by:

September 6, 2005
September 8, 2005
May 12, 2008
March 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00149097 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Role of the Autonomic Nervous System in HIV-Lipodystrophy
Autonomic Nervous System Activity in the Pathogenesis of the Lipodystrophy Syndrome in HIV-Infected Patients.
The study aims to characterise the influence of the autonomic nervous system activity on the development of the lipodystrophy syndrome in HIV-infected patients by measuring heart rate variability and various metabolic pathways in HIV patients receiving highly active antiretroviral therapy.
Not Provided
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Serum and Plasma
Non-Probability Sample
Patients with confirmed HIV infection and no active opportunistic infection during the last 2 months.
  • HIV Infections
  • Lipodystrophy-Syndrome
Not Provided
Not Provided
Fliers E, Sauerwein HP, Romijn JA, Reiss P, van der Valk M, Kalsbeek A, Kreier F, Buijs RM. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 2003 Nov 22;362(9397):1758-60.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2007
Not Provided

Inclusion Criteria:

  • HIV-infection
  • Age above 18 years
  • No AIDS defining event during last 6 months
  • No infection during last 6 weeks
  • No concommitant drug interfering with insulin sensitivity and ANS-activity
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Prof. Georg Behrens, Hannover Medical School
Hannover Medical School
HW&J Hector-Stiftung
Principal Investigator: Georg MN Behrens, MD Hannover Medical School
Hannover Medical School
May 2008